首页|半夏白术天麻汤加减治疗H型高血压有效性和安全性的Meta分析

半夏白术天麻汤加减治疗H型高血压有效性和安全性的Meta分析

扫码查看
目的:系统评价半夏白术天麻汤加减治疗 H 型高血压的疗效和安全性。方法:计算机检索中国知网(CNKI)、万方数据库(WanFang Data)、维普、中国生物医学文献数据库、PubMed、EMbase等中英文数据库,检索时限均为建库至 2022 年 2 月 25 日,收集半夏白术天麻汤加减(试验组)对比常规西药(对照组)治疗 H型高血压的随机对照试验(RCT)。筛选文献并提取资料,同时采用Cochrane系统评价员手册 5。1。0推荐的偏倚风险评估工具评价纳入文献质量,运用 RevMan 5。4软件进行 Meta分析。结果:共纳入17项 RCT,涉及 1 327例病人。Meta分析结果显示,试验组血同型半胱氨酸(Hcy)水平[SMD=-2。77,95%CI(-3。52,-2。02),P<0。000 01]、收缩压[MD=-10。42,95%CI(-12。91,-7。93),P<0。000 01]、舒张压[MD=-8。92,95%CI(-10。38,-7。46),P<0。000 01]、C反应蛋白(CRP)水平[MD=-10。73,95%CI(-11。34,-10。11),P<0。000 01]、基质金属蛋白酶 9(MMP-9)水平[MD=-16。17,95%CI(-17。04,-15。30),P<0。000 01]、肿瘤坏死因子-α(TNF-α)水平[MD=-30。69,95%CI(-31。90,-29。47),P<0。000 01]、不良反应发生率[RR=0。38,95%CI(0。15,0。92),P=0。03]均明显低于对照组,叶酸[MD=7。11,95%CI(6。61,7。61),P<0。000 01]、维生素 B12水平[SMD=2。44,95%CI(2。11,2。77),P<0。000 01]、临床疗效总有效率[RR=1。21,95%CI(1。15,1。28),P<0。000 01]均明显高于对照组。结论:现有证据表明,半夏白术天麻汤加减有可能提高 H型高血压病人的临床疗效,降低 Hcy水平,减少不良反应,安全性更高,但临床疗效结论仍需扩大样本量进一步验证。
Meta-analysis of Efficacy and Safety of Banxia Baizhu Tianma Decoction in the Treatment of H-type Hypertension
Objective:To systematically review the efficacy and safety of Banxia Baizhu Tianma Decoction in the treatment of H-type hypertension.Methods:Chinese and English databases such as CNKI,WanFang Data,VIP,China Biomedical Literature Database,PubMed,and EMbase were searched for randomized controlled trials(RCTs)comparing Banxia Baizhu Tianma Decoction(test group)with conventional western medicine(control group)for the treatment of H-type hypertension from inception until February 25,2022.Literatures was screened and data were extracted.At the same time,the quality of the included literature was evaluated using the bias risk assessment tool recommended in the Cochrane Manual of Systematic Reviewers 5.1.0.The RevMan 5.4 software was used for Meta-analysis.Results:A total of 17 RCTs with 1 327 patients were included.The results of Meta analysis showed that the homocysteine(Hcy)level(SMD=-2.77,95%CI-3.52--2.02,P<0.000 01),systolic blood pressure(MD=-10.42,95%CI-12.91--7.93,P<0.000 01),diastolic blood pressure(MD=-8.92,95%CI-10.38--7.46,P<0.000 01),C-reactive protein(CRP)level(MD=-10.73,95%CI-11.34--10.11,P<0.000 01),matrix metalloproteinase 9(MMP-9)level(MD=-16.17,95%CI-17.04--15.30,P<0.000 01),tumor necrosis factor-α(TNF-α)level(MD=-30.69,95%CI-31.90--29.47,P<0.000 01),and the incidence of adverse reactions(RR=0.38,95%CI 0.15-0.92,P=0.03)in experiment group were significantly lower than those in control group,and the folic acid level(MD=7.11,95%CI 6.61-7.61,P<0.000 01),vitamin B12 level(SMD=2.44,95%CI 2.11-2.77,P<0.000 01),total effective rate of clinical efficacy(RR=1.21,95%CI 1.15-1.28,P<0.000 01)were significantly higher than those in control group.Conclusion:Available evidence suggests that modification of Banxia Baizhu Tianma Decoction may improve the clinical efficacy in the treatment of H-type hypertension,effectively reduce the level of Hcy,with fewer adverse reactions and higher safety,but the clinical efficacy conclusion still needs to be further verified by expanding the sample size.

H-type hypertensionBanxia Baizhu Tianma DecoctionMeta-analysisefficacy

李志情、韦玉连、孙文昊、黄绮恩、温睿诗、唐耀平

展开 >

广西中医药大学(南宁 530200)

广西中医药大学附属瑞康医院(南宁 530011)

广西高发传染病中西医结合转化医学重点实验室(南宁 530200)

H型高血压 半夏白术天麻汤 Meta分析 疗效

国家自然科学基金国家自然科学基金广西中医药大学博士科研启动基金(2020)

81774115821608562020BS035

2024

中西医结合心脑血管病杂志
中国中西医结合学会 山西医科大学第一医院

中西医结合心脑血管病杂志

CSTPCD
影响因子:1.463
ISSN:1672-1349
年,卷(期):2024.22(16)